PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Proliferation of Lifestyle Diseases Augments Prospects for the Cardiovascular Drugs Market in Saudi Arabia and the UAE Finds Frost & Sullivan - Expanding base of ageing population fuels market growth - Pharma.Frost.com
Proliferation of Lifestyle Diseases Augments Prospects for the Cardiovascular Drugs Market in Saudi Arabia and the UAE Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Dubai, UAE, United Arab Emirates, 2011/11/09 - Expanding base of ageing population fuels market growth - Pharma.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The high incidence of lifestyle diseases, including obesity, hypertension and diabetes, in the UAE is the key factor driving growth in the cardiovascular drugs market. In the Kingdom of Saudi Arabia (KSA), the prominent growth drivers are the demographic shift toward baby boomers, the increasing incidence of cardiovascular diseases and mandatory health insurance for expatriate employees.

The cardiovascular drugs market in KSA witnessed double-digit growth from 2007 to 2010. The total pharmaceutical market in the UAE generated revenue of USD$1.3 billion, in 2010 and cardiovascular drugs contributed around 7.5 per cent of the total market revenue.

New analysis from Frost & Sullivan (pharma.frost.com), Analysis of Cardiovascular Drugs Market in Saudi Arabia and the United Arab Emirates, finds that the KSA and UAE markets earned revenue of USD $100.2 million and USD $172.8 million in 2010 and are expected to grow at a CAGR of 16.5 per cent and 17.6 per cent to reach USD $291.4 million and USD $537.1 million in 2017, respectively.

"Within the cardiovascular drugs market, antihypertensives held the largest share of almost 60 per cent of the revenue in 2010, followed by antidyslipidemics (lipid lowering), which held a 37 per cent share," says Frost & Sullivan Pharmaceuticals Research Analyst. "The 'other' segment held a share of around three per cent."

Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs) within the antihypertensives segment are the most preferred drugs in both the markets. Statins are the most-used drug class among antidyslipidemics in both markets.

The patent expiry of the key innovative molecules, stringent regulatory processes and government's encouragement of generics along with low patient compliance in the cardiovascular segment are the growth bottlenecks in the cardiovascular markets in KSA and UAE. In particular, many cardiovascular drugs including blockbusters will soon be off-patent and such expiries are not being replaced with new molecules.

"The government is patronizing generics to control spiralling healthcare and support the domestic pharmaceutical companies," observes the Analyst. "Although genericization is expected to propel consumption of medicines, it is likely to negatively impact the market size in terms of value."

Going forward, all three market segments - antihypertensive, lipid lowering and others (including multi-therapy combination drugs) are expected to grow. Identifying and targeting the right molecule within the market segments will ensure strong business traction.

Growth in the lipid-lowering drugs segment is expected to outpace that in the other segments. Their proportionate contribution to the total cardiovascular drugs market is likely to increase due to the higher incidence of dyslipidemia and modifications of guidelines for normal low density lipoprotein (LDL) level from 120mg/dl to 100mg/dl.

If you are interested in more information on this study, please send an email with your contact details to Deepshri Iyer/ Nimisha Iyer Corporate Communications, at deepshrii[.]frost.com/ niyer[.]frost.com with your full name, company name, title, telephone number, company email address, company website, city, state and country.

Analysis of Cardiovascular Drugs Market in Saudi Arabia and the United Arab Emirates is part of the Pharmaceuticals & Biotechnology Growth Partnership Service program, which also includes research in the following markets: European Diabetes Therapeutics Market, 2011 U.S. Diabetes Injection Pens Features and Global CRO Market: Quantitative Assessment. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Analysis of Cardiovascular Drugs Market in Saudi Arabia and the United Arab Emirates
P51B-52

Contact:
Tanu Chopra, Corporate Communications - Middle East and North Africa
P: +91 22 6607 2037 / F: +91 22 2832 4713 / E: tanu.chopra[.]frost.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Proliferation of Lifestyle Diseases Augments Prospects for the Cardiovascular Drugs Market in Saudi Arabia and the UAE Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Deepshri Iyer / Nimisha Iyer 
+91 22 6607 2038 / +91 98200 50519 deepshrii[.]frost.com / niyer[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)